A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
Public ClinicalTrials.gov record NCT03470922. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma
Study identification
- NCT ID
- NCT03470922
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 714 participants
Conditions and interventions
Conditions
Interventions
- Relatlimab Biological
- Nivolumab Biological
Biological
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 10, 2018
- Primary completion
- Jan 24, 2021
- Completion
- Dec 14, 2030
- Last update posted
- Sep 8, 2025
2018 – 2030
United States locations
- U.S. sites
- 22
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0010 | Tucson | Arizona | 85724-5024 | — |
| Local Institution - 0020 | Los Angeles | California | 90095 | — |
| Coastal Integrative Cancer Care | San Luis Obispo | California | 93401 | — |
| Local Institution - 0116 | Santa Barbara | California | 93105 | — |
| Local Institution - 0012 | Washington D.C. | District of Columbia | 20007 | — |
| Local Institution - 0013 | Jacksonville | Florida | 32224 | — |
| Local Institution - 0117 | Orlando | Florida | 32806 | — |
| Local Institution - 0007 | Tampa | Florida | 33612 | — |
| Local Institution - 0038 | Atlanta | Georgia | 30342 | — |
| Local Institution - 0016 | Chicago | Illinois | 60611 | — |
| Local Institution - 0114 | Fort Wayne | Indiana | 46804 | — |
| Local Institution - 0077 | Baltimore | Maryland | 21237 | — |
| Local Institution - 0120 | Baltimore | Maryland | 21287 | — |
| Local Institution - 0014 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0134 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0015 | Ann Arbor | Michigan | 48109 | — |
| Local Institution - 0009 | Minneapolis | Minnesota | 55407 | — |
| Local Institution - 0011 | Rochester | Minnesota | 55905 | — |
| Local Institution - 0018 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 0019 | Allentown | Pennsylvania | 18103 | — |
| Local Institution - 0076 | Dallas | Texas | 75246 | — |
| Local Institution - 0008 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 105 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03470922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 8, 2025 · Synced Jul 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03470922 live on ClinicalTrials.gov.